June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Analysis of the factors influencing additional intravitreal bevacizumab injection against diabetic macular edema
Author Affiliations & Notes
  • Joseph Kim
    Inha University Hospital, Incheon, Korea (the Republic of)
  • Hee Seung Chin
    Inha University Hospital, Incheon, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Joseph Kim, None; Hee Seung Chin, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1897. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Joseph Kim, Hee Seung Chin; Analysis of the factors influencing additional intravitreal bevacizumab injection against diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1897.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the factors associated with additional intravitreal bevacizumab injection against diabetic macular edema(DME) including systemic factors.

Methods : Medical records for 114 eyes of 99 patients with diabetic macular edema were retrospectively reviewed. All patients received intravitreal bevacizumab injection of 1.25mg (0.05cc) at baseline. The injection was repeated when DME aggravated. We analyzed the correlation between the number of additional injections for 12 months and various factors as follows; (1) Systemic factors: Hypertension, HbA1c, eGFR, Duration of diabetes, (2) Ocular factors: history of panretinal photocoagulation (PRP), Central macular thickness (CMT) and macular volume (MV), and DME OCT types; diffuse retinal thickening (DRT), cystoid macular edema (CME), serous retinal detachment (SRD).

Results : DME OCT type, CMT and MV at 1month after baseline were significantly related to the number of additional injections (P < 0.05). The mean number of injections over 12 months was different among the DME OCT Types (DRT = 2.67, CME = 4.01, SRD = 4.10; P=0.049). CMT and MV at 1month after baseline had positive correlation with more additional bevacizumab injection (CMT, Exp(B) = 1.027 (95% CI = 1.007-1.048, P=0.008); MV, Exp(B) = 2.013 (95% CI = 1.079-3.574, P=0.028). On the other hand, other factors were not correlated with the number of the injections (P > 0.05).

Conclusions : In terms of OCT types, patients with DRT maintained an anatomical improvement with fewer additional intravitreal bevacizumab injections over 12 months. The greater the CMT and MV values at 1month after baseline, the more injections were required.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×